Breaking News

Financial Report: Alkermes

April 30, 2014

Manufacturing and royalty revenues down 24% in the quarter

1Q Revenues: $130.2 million (-20%)
1Q Loss: $24.4 million (earnings were $3.0 million in 1Q13)
Comments: Manufacturing and royalty revenues were $111.3 in the quarter, down 24%, with AMPYRA/FAMPYRA down 17% to $20.6 million. Manufacturing and royalty revenues from the company’s antipsychotic franchise, RISPERDAL CONSTA and INVEGA SUSTENNA/XEPLION, were $49.6 million, up 9%. VIVITROL sales were $17.1 million, up 17%. Royalty revenue from BYDUREON was $7.7 million, up 60%. R&D expenses were $52.1 million, up 46% reflecting increased investment in the company’s CNS pipeline.
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors